ArticleEuropean thyroid journal2013
2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.
Article in European thyroid journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 3 syntheses or guidelines pooled it, 278 citations in OpenAlex.
- 2026 ETA guideline on interference in immunoassay measurements used in assessment of thyroid function.European thyroid journal · 2026Guideline
- 2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action.European thyroid journal · 2024Guideline
- Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management.Pituitary · 2019Pooled it
- STING expression in pituitary neuroendocrine tumour immune microenvironments.Endocrine-related cancer · 2026Article
- Hyperthyroidism, acromegaly, and hyperprolactinemia in a patient with a mature plurihormonal PIT-1 lineage adenoma.JCEM case reports · 2026Article
- Thyrotropin/growth hormone co-secreting pituitary adenoma with pancytopenia: a case report.Journal of medical case reports · 2026Article
- Impacts of new sex- and age-specific TSH and FT4 reference ranges on thyroid status and metabolic disorder associations.Journal of the Endocrine Society · 2026Article
- Cardiac Tamponade, Pituitary Hyperplasia, and Macroorchidism in Severe Primary Hypothyroidism.JCEM case reports · 2026Article
- Article
- Patients With Pituitary Neuroendocrine Tumours Requiring Neurosurgery -Who Is Referring Them?Clinical endocrinology · 2026Article
- The clinical value of [Pituitary · 2026Observational
- Article
- Association between the WHO 2017 and 2022 classification updates and ICD-10 code accuracy in patients with PitNETs: a real-world retrospective study.BMC endocrine disorders · 2026Article
- How to manage autoimmune hyperthyroidism (Graves' disease): from differential diagnosis to emerging immunological therapies.Drugs in context · 2026Review
- Traditional Chinese Medicine as an Adjunct in Hyperthyroidism Management: A Narrative Review of Pathophysiology, Proposed Mechanisms, and Clinical Evidence.International journal of general medicine · 2026Review
- Article
- The PitNET Puzzle: From Zero to Linking Molecular Behavior with Neurosurgical Aspects.Medicina (Kaunas, Lithuania) · 2025Review
- Pituitary adenoma extended to the basilar sinus: Lessons from anatomical and radiological studies (Experimental Research).Neurosurgical review · 2025Article
- A subtle initial clinical presentation of a TSH-secreting PitNET.Endocrinology, diabetes & metabolism case reports · 2025Article
- Observational
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Hyperthyroidism is mainly due to autoimmune thyroid disorders or toxic goiter, and very rarely to the presence of thyrotropin (TSH)-secreting pituitary adenomas (TSHomas). These tumors are characterized by high levels of circulating free thyroid hormones (FT4 and FT3) in the presence of nonsuppressed serum TSH concentrations. Failure to correctly diagnose TSHomas may result in inappropriate thyroid ablation, which results in a significant increase of pituitary tumor mass. The diagnosis is mainly achieved by measuring TSH after T3 suppression and TRH stimulation tests. These dynamic tests, together with pituitary imaging and genetic testing are useful in distinguishing TSHomas from the syndromes of resistance to thyroid hormone action. The treatment of choice is surgery. In cases of surgical failure, somatostatin analogs have been found to be effective in normalizing TSH secretion in more than 90% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.